Gainers
- Sierra Oncology, Inc. (NASDAQ:SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-approved JAK inhibitor. The company also entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential launch of momelotinib.
- Aptorum Group Limited (NASDAQ:APM) shares gained 38.9% to close at $22.68 after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation to Aptorum Group’s SACT-1, a repurposed small molecule compound for Neuroblastoma.
- Exela Technologies, Inc. (NASDAQ:XELA) jumped 33% to settle at $0.55 after the company announced a renewal of its services contract with a consulting firm. The total contract value is over $35 million.
- Vistas Media Acquisition Company Inc. (NASDAQ:VMAC) gained 27.3% to close at $13.90. Vistas Media Acquisition Company shareholders recently approved a business combination with Anghami.
- Aditxt, Inc. (NASDAQ:ADTX) gained 25.7% to close at $0.4549. Aditxt recently reported submission of 2 requests for emergency use authorization to the FDA for AditxtScore for covid-19 tests to measure quantity and quality of antibodies against covid and variants including omicron.
- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) jumped 25.5% to close at $1.17 after the company announced the FDA cleared its Investigational New Drug application, allowing its Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder to proceed.
- SmileDirectClub, Inc. (NASDAQ:SDC) gained 24.6% to close at $2.48 after the company announced strategic actions to increase profitability.
- ClearOne, Inc. (NASDAQ:CLRO) jumped 23.5% to settle at $1.07.
- Bally's Corporation (NYSE:BALY) rose 22.7% to close at $35.85. Standard General, Bally's largest shareholder, submitted proposal to acquire all of the outstanding shares of Bally's common stock not currently owned by the company at a price of $38 per share.
- Capricor Therapeutics, Inc. (NASDAQ:CAPR) gained 21.6% to close at $20.28. Capricor Therapeutics said it has entered into a partnership with Japanese pharma company Nippon Shinyaku for the exclusive commercialization and distribution in the U.S. of Capricor's lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy.
- Urban One, Inc. (NASDAQ:UONE) gained 21% to settle at $5.07.
- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) jumped 20.6% to close at $0.2123. China SXT Pharmaceuticals recently priced a $3.5 million underwritten public offering of ordinary shares.
- Nine Energy Service, Inc. (NYSE:NINE) gained 20.5% to close at $1.35.
- Silence Therapeutics plc (NASDAQ:SLN) jumped 20.3% to settle at $21.89.
- Progenity, Inc. (NASDAQ:PROG) gained 20.3% to close at $1.54. Progenity recently announced acceptance of two abstracts on treatment of gastrointestinal disorders at ECCO'22.
- Digital Brands Group, Inc. (NASDAQ:DBGI) rose 18.4% to close at $1.5150. Digital Brands Group recently announced a definitive agreement to acquire Sundry.
